Prevalence of Myocardial Scars on CMR After COVID-19 Infection

NACompletedINTERVENTIONAL
Enrollment

231

Participants

Timeline

Start Date

June 13, 2020

Primary Completion Date

April 4, 2022

Study Completion Date

April 4, 2022

Conditions
COVID-19Virus Disease
Interventions
DEVICE

Contrast-enhanced CMR

Cardiac Magnetic Resonance Imaging (MRI) examinations will be performed at Day 0 visit on clinical systems 1.5 equipped with specific antennas for cardiac imaging. The imaging protocol will last approximately 50 minutes.

DIAGNOSTIC_TEST

Exercise test ECG

"A treadmill exercise test with 12 lead ECG monitoring will be performed at M3 visit.~Maximum expected enrollment 30 MRI+ patients and 30 healthy volunteers MRI- matched controls."

BIOLOGICAL

Blood sample

"A blood sample will be taken at Day 0 visit for COVID-19 serology, hematocrit measurement, ultra-high sensitive troponin test, low grade markers of inflammation, genetic profiling.~An other blood sample will be taken at M3 visit for a control COVID-19 serology for 30 healthy volunteers."

DIAGNOSTIC_TEST

Resting 12 lead ECG

A resting 12 lead ECG will be performed at Day 0 visit.

DIAGNOSTIC_TEST

24 hour Holter ECG

A 24 hour Holter ECG will be performed at M3 visit. Maximum expected enrollment 30 MRI+ patients and 30 healthy volunteers MRI- matched controls.

Trial Locations (1)

33604

Bordeaux University Hospital, Pessac

All Listed Sponsors
collaborator

Grant Agreement ERC n°715093

UNKNOWN

collaborator

University of Bordeaux

OTHER

lead

University Hospital, Bordeaux

OTHER

NCT04636320 - Prevalence of Myocardial Scars on CMR After COVID-19 Infection | Biotech Hunter | Biotech Hunter